• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Folic Acid Analog
    3 Drugs classified under this drug class


    All the Drug Class Drugs

    Abitrexate
    Salomon, Levin & Elstein Ltd
    RX
    partial basket chart
    Abitrexate

    Folic Acid Analog. Methotrexate 25 mg/ml.
    VIAL (sol. for inj.): 25 mg/ ml X 2 ml, 4 ml,
    8 ml, 20 ml, 40 ml. Dose must be ajust.
    individ. for each pt. accord. to med.
    cond. See lit.
    Antineopl. Chemother.
    Tmt. of gestational choriocarcinoma,
    chorioadenoma destruens and
    hydatidiform mole. Palliation of ALL. Tmt.
    and proph. of menin. leukemia.
    Greatest effect has been observed in
    palliation of acute lymphoblast.(stemcell)
    leukemias in child. In comb. with
    other anticancer agents, may be used for
    the induc. of remis.,but is most common.
    used in the mainten. of induced remis.
    May be used alone, or in comb. with other
    antineoplastic drugs, in the manag. of
    breast canc., epidermoid cancers of the
    head and neck, lung cancer (partic.
    squamous cell ,small cell types), bladder
    cancer and osteogenic cancer. Tmt. of the
    advan.stages (III and IV, Peter’s Staging
    system) of lymphosarcoma, partic. in
    child., and in advanced cases of mycosis
    fungoides.
    Psoriasis. Indic. only in the sympt. control
    of sev. recalcitrant, disabling psoriasis
    which is not adeq. responsive to other
    forms of therapy, and only when the diag.
    has been established, as by biopsy and/or
    after dermat. consult. RA:Tmt. of selec.
    adul.with sev. RA, only when the diag. has
    been well established accord. to rheumat.
    standards, with inadeq. response to other
    forms of antirheum. ther., includ. full dose
    NSAIDs and usually a trial of at least one
    or more dis.-modif. antirheum. drugs.
    C/I: Pregnancy, lact., pts. in poor state of
    nutrition, sev. ren. impair. (crCL <20 ml/
    min), sev. liver impair., bone marrow
    hypoplasia, leucopenia,
    thrombocytopenia, anemia, alcohol
    abuse, hypersens. and lung toxic.due to
    methotrexate, serious, acute or chronic
    infect. such as tuberculosis and HIV,
    ulcers of the oral cavity and known
    active GI ulcer dis. Concur. vaccin. with
    live vaccines.

    Difolta
    Rafa
    RX
    partial basket chart
    Difolta

    Folic Acid Analog. Pralatrexate 20 mg/ml.
    VIAL (sol. for inject.): 1 x 20 mg/ml; 40
    mg/ 2 ml. 30 mg/m² admin. as I.V. push
    over 3-5 mins via side port of free-flow.
    0.9% sod. chlor. inject., USP I.V. line 1 x
    wkly for 6 wks in 7-wk. cycles until dis.
    progress./unaccept. toxicity. Admin.
    under vis. of qualified phys.
    experienced in antineoplastic agents.
    See lit.
    Tmt. relapsed or refract. peripheral T-cell
    lymphoma (PTCL).

    Pemetrexed Teva
    Abic
    RX
    partial basket chart
    Pemetrexed Teva

    Folic Acid Analog. Pemetrexed 100, 500, 1000 mg.
    VIAL (Pwdr. for conc. for sol. for infus.): 1 x 100 mg, 500 mg, 1000 mg. Tmt. to be initiated by physician experienced in the use of anticancer ther. In comb. with cisplatin: recomm. dose is 500 mg/m2 of BSA admin. as IV infus. over 10 min. on the 1st day of each 21 d cycle. The recomm. dose of cisplatin is 75 mg/m2 BSA infus. over 2 h approx. 30 min. after completion of pemetrexed infus. on the 1st  d of each 21 d cycle. As single agent: In pts. treated for NSCLC after prior chemother., the recomm. dose is 500 mg/m2 BSA admin. as IV infus. over 10 min. on the 1st d of each 21d cycle. See lit.
    Malignant pleural mesothelioma: in comb. with cisplatin is indic. for the tmt. of pts. with malign. pleural mesothelioma whose dis. is unresectable or who are otherwise not candidates for curatible surgery. Non-small cell lung cancer: In comb. with cisplatin is indic. for the 1st  line tmt. of pts. with locally adv. or metast. non-small cell lung cancer other than predominantly squamous cell histology. As monother. for the mainten. tmt. of locally adv. or metast. non-small cell lung cancer other than predominantly squamous cell histology in pts. whose dis. has not progressed immed. follow. platinum-based chemotherapy.  As monother. for the 2d  line tmt. of pts. with locally adv. or metast. non-small cell lung cancer other than predominantly squamous cell histology.
    C/I: Hypersens., Lact., Concom. yellow fever vacc.

    CLOSE